{"entity":{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","aka":[],"tldr":"A phase 3 trial testing AL2846 in thyroid cancer, now recruiting.","summary":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma is a phase 3 interventional study registered as NCT06860971, led by Chia Tai Tianqing Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy. Planned enrolment is 144 participants (estimated). The study started in 2025-04-18 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06860971","url":"https://clinicaltrials.gov/study/NCT06860971"}],"tags":["ctgov-ingest"],"related":[],"indications":["thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":["al2846"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06860971","phase":"3","setting":"A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy","sponsor":"Chia Tai Tianqing Pharmaceutical","enrolled":144,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06860971/","neighbours":{"indication":[{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/"}],"drug":[{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/"}]}}